FORT WORTH, Texas, Nov. 13 /PRNewswire-FirstCall/ -- Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM - News), announced today the 510k clearance of a new wound management product utilizing their patented hydrolyzed collagen technology.
The new addition to our product line (patent pending) combines hydrolyzed collagen with the healing properties of polysulfated glycosaminoglycan (PSGAG) and will initially be available in gel form. PSGAG enhances the absorptive capacity of the hydrolyzed collagen gel, making it appropriate for the management of exudative wounds. In addition, PSGAG has been shown to prepare the granulation tissue for epidermal migration by maintaining a uniform, low density granulation tissue more easily modified by the migrating epithelium thus improving the rate of epithelialization of a chronic wound and reducing scarring.
The product has been cleared and is indicated for topical use in the management of chronic and acute wounds and dermal ulcers including the management of:
-- Pressure Ulcers (Stages I-IV)
-- Venous Stasis Ulcers
-- Diabetic Ulcers
-- First and Second Degree Burns
-- Surgical Wounds
-- Traumatic wounds
-- Superficial Wounds
-- Ulcers resulting from arterial insufficiency
-- Grafted wounds and donor sites
“We are delighted with the FDA clearance of the hydrolyzed collagen with polysulfated glycosaminoglycan (PSGAG),” states Cathy Bradshaw, President of Wound Care Innovations. “This allows us to bring to the high margin, advanced wound care market, a product that utilizes our proven, patented hydrolyzed collagen and incorporates the distinctive characteristics of PSGAG to prepare the wound bed for re-epithelialization, wound closure.”
Costs associated with wound care are significant, exceeding billions of dollars annually. “We are introducing a new, improved product which addresses the epithelialization of healing wounds and will be cost effective, patient ready and easy to use in all health care settings. The product is cost effective both in terms of direct and indirect costs. We are encouraged by initial test observations which promise improved clinical outcomes for the patient. Our expectations are high. We expect our hydrolyzed collagen with Polysulfated Glycosaminoglycan to contribute significantly to our growth moving forward.”
About Wound Management Technologies, Inc.:
Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM - News), with its corporate headquarters in Fort Worth, Texas, markets and distributes wound care products to the healthcare market under patented technology licensed to the Company. The Company is positioned and seeks to be a leading provider of wound care products. For more information on the Company please visit the Company’s Website at www.Celleraterx.com .
“Safe Harbor” Statement: Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company’s expectations with regard to the future impact on the company’s results from new products in development are “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company’s actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company’s operations, current and future performance and financial condition. These items involve risks and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks and uncertainties detailed in the Company’s SEC filings. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
For Further Information:
Product Information Shareholder Relations Cathy Bradshaw Lucy Singleton President Secretary 954-315-9242 817-820-7080
Source: Wound Management Technologies, Inc.
